Micaela Morelli – författare

Immunotherapies for Neurological Disorders: Unlocking the Brain's Defenses explores the complex intersection of both the immune and nervous systems and neurological disorders. This comprehensive guide details the vital role of immunology in understanding conditions from Alzheimer's and Parkinson's to autoimmune diseases like multiple sclerosis and Guillain-Barr� syndrome. Each chapter reviews strategies, including the use of antibodies, recombinant proteins, and cutting-edge vaccine approaches to modulate immune responses in the brain. Readers will be presented with the therapeutic potential of immune cells, gene therapy, and RNA interference in combating these debilitating disorders, while also examining the role of nanotechnology in enhancing treatment efficacy.Aimed at neurologists, immunologists, researchers, and students alike, this book serves as an essential resource for the latest advancements in neurological disease treatment.Examines innovative treatment strategies, including antibodies, recombinant proteins, and vaccinesReviews the therapeutic potential of immune cells, gene therapy, and RNA interference in addressing various neurological conditionsHighlights the latest advancements in immunology relevant to neurodegenerative and autoimmune diseases

Adenosine A2A receptor antagonists have shown great promise in the treatment of Parkinson's Disease and alleviation of symptoms. This book addresses various aspects of this class of drugs from their chemical development to their clinical use. Among the many insightful chapters contained in this book, there are three unique reviews that have not previously been published in any format: (1) a history of istradefylline, the first A2A antagonist approved for treatment of Parkinson's Disease, (2) an overview of neuroimaging studies in human death and disease and (3) a study of urate as a possible biomarker and neuroprotectant.

Adenosine A2A receptor antagonists have shown great promise in the treatment of Parkinson''s Disease and alleviation of symptoms. This book addresses various aspects of this class of drugs from their chemical development to their clinical use. Among the many insightful chapters contained in this book, there are three unique reviews that have not previously been published in any format: (1) a history of istradefylline, the first A2A antagonist approved for treatment of Parkinson''s Disease, (2) an overview of neuroimaging studies in human death and disease and (3) a study of urate as a possible biomarker and neuroprotectant.